Genmab Achieves Positive Results in NHL Study

Genmab achieved positive results from a Phase II study of Arzerra (ofatumumab) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in front line follicular non-Hodgkin’s lymphoma (NHL).

The study included a total of 58 patients with previously untreated NHL. The overall response rate (ORR) in patients treated with 500 mg of ofatumumab was 90%, including 24% complete remissions (CR), and 45% complete remissions/unconfirmed (CRu). In patients treated with 1000 mg of ofatumumab, the ORR was 100% including 38% CR, and 17% CRu.

There were no unexpected safety findings reported during treatment and within 30 days after last infusion. The most common adverse events of grade 3 or 4 (greater than 10%) were leucopenia and neutropenia. No events of sepsis or pneumonia were observed, and no deaths reported in the trial.

“We are pleased with the positive results shown in this study and believe they are indicative of the potential of ofatumumab in the treatment of front line follicular non-Hodgkin’s lymphoma,” said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab. Ofatumumab is being developed under a co-development and commercialization agreement with GlaxoSmithKline.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference